Modelling of doxycycline-based prevention of bacterial sexually transmitted infections in comparison to condom-based and test-based prevention.

Chlamydia trachomatis Mycoplasma genitalium Neisseria gonorrhoeae STI Treponema pallidum condom doxycycline prevention prophylaxis testing-as-prevention

Journal

European journal of microbiology & immunology
ISSN: 2062-509X
Titre abrégé: Eur J Microbiol Immunol (Bp)
Pays: Hungary
ID NLM: 101569896

Informations de publication

Date de publication:
30 Jan 2024
Historique:
received: 21 12 2023
accepted: 17 01 2024
medline: 30 1 2024
pubmed: 30 1 2024
entrez: 30 1 2024
Statut: aheadofprint

Résumé

Doxycycline-based prevention of bacterial sexually transmitted infections (STIs) has been assessed in various studies and has been recommended by the European AIDS Clinical Society to be proposed to persons with repeated STIs on a case-by-case basis. However, while good preventive effects could be shown for Chlamydia trachomatis and Treponema pallidum in Europe, no reliable prevention against doxycycline resistance-affected bacterial causes of STIs like Neisseria gonorrhoeae and Mycoplasma genitalium was confirmed. In a modelling-approach, we assessed potential beneficial effects even against the latter microorganisms in case of optimized adherence with doxycycline prevention. These effects were modelled for Germany in comparison to traditional prevention schemes like condom-based STI-prevention and testing-as-prevention. With estimated risk reduction in the ranges of 86% for N. gonorrhoeae and of 82% for Mycoplasma genitalium, expectable preventive efficacy similar to alternative preventive approaches could be calculated in case of optimized adherence with doxycycline prevention. In case of repeated risk exposure, the preventive potential of condom-based prevention was decreased compared to both optimized doxycycline prevention and testing-as-prevention. As suggested by the applied modelling, the preventive effect of optimized doxycycline prevention against bacterial STIs is in a similar range, like other common prevention strategies.

Sections du résumé

Background UNASSIGNED
Doxycycline-based prevention of bacterial sexually transmitted infections (STIs) has been assessed in various studies and has been recommended by the European AIDS Clinical Society to be proposed to persons with repeated STIs on a case-by-case basis. However, while good preventive effects could be shown for Chlamydia trachomatis and Treponema pallidum in Europe, no reliable prevention against doxycycline resistance-affected bacterial causes of STIs like Neisseria gonorrhoeae and Mycoplasma genitalium was confirmed.
Methods UNASSIGNED
In a modelling-approach, we assessed potential beneficial effects even against the latter microorganisms in case of optimized adherence with doxycycline prevention. These effects were modelled for Germany in comparison to traditional prevention schemes like condom-based STI-prevention and testing-as-prevention.
Results UNASSIGNED
With estimated risk reduction in the ranges of 86% for N. gonorrhoeae and of 82% for Mycoplasma genitalium, expectable preventive efficacy similar to alternative preventive approaches could be calculated in case of optimized adherence with doxycycline prevention. In case of repeated risk exposure, the preventive potential of condom-based prevention was decreased compared to both optimized doxycycline prevention and testing-as-prevention.
Conclusions UNASSIGNED
As suggested by the applied modelling, the preventive effect of optimized doxycycline prevention against bacterial STIs is in a similar range, like other common prevention strategies.

Identifiants

pubmed: 38289395
doi: 10.1556/1886.2023.00059
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Andreas Hahn (A)

1Institute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, Rostock, Germany.

Hagen Frickmann (H)

1Institute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, Rostock, Germany.
2Department of Microbiology and Hospital Hygiene, Bundeswehr Hospital Hamburg, Hamburg, Germany.

Ulrike Loderstädt (U)

3Institute for Infection Control and Infectious Diseases, University Medical Center Göttingen, Göttingen, Germany.

Classifications MeSH